On September 1st, 2022, the "2022CHC·Citic Securities Healthcare Conference and the 11th China MedTec CEO Summit" jointly hosted by CHC Healthcare Consulting and Citic Securities, was held in Hefei, Anhui Province. The conference focused on cutting-edge research and held a special forum on surgical robots. As the strategic partner of the conference and the leader of the vascular interventional surgery robot field, RainMed Medical was invited to attend the forum. Mr. Kangjian Liu, Vice president and Secretary of the Board announced that RainMed Medical will build a platform-level vascular interventional surgery robot to promote the realization of an  unmanned operating room with automated diagnosis and treatment. This forum deeply discussed the surgical robot in terms of technology progress, business model, industrial policy, etc. RainMed Medical had an in-depth communication and discussion on the vascular interventional surgery robot with other leading enterprises in the industry, such as TINAVI Medical Technologies, Beijing Sugerii Technology, Define Vascular Operation and Harbin Intelligent Surgery Equipment, etc.

With the Policy Support and Technological Breakthrough, the Domestic Surgical Robot Industry Has Entered a Stable and Rapid Development Channel

If we regard the medical device as a crown, Surgical robot is like the pearl on the crown. It is a medical device integrating many fields such as medicine, mechanics, biomechanics and computer science. Compared with other surgical robots, vascular interventional surgery deals with fragile blood vessels, which has higher requirements for product performance and stability. Only when the robot structure, image navigation, virtual force feedback, and surgical planning cooperate effectively, the robot’s performance can reach the best. Therefore, the research progress of vascular interventional surgery robot was relatively slow.

In recent years, China has vigorously supported the development of innovative medical devices. Corresponding measures have been introduced to promote the development of innovative medical devices in terms of industry and medical insurance, etc. Policy support has stimulated the innovation vitality of the enterprises and helped to realize the magnificent transformation of the robot "from nothing to something, from something to everything". "I always believe in the wisdom of Chinese people, despite the technical barriers of vascular interventional surgery robots." said by Kangjian Liu , vice president and board secretary of RainMed Medical. As long as there is faith and perseverance, domestic surgical robots will eventually achieve rapid development. Under the guidance of national policies and the leadership of leading enterprises in the industry, surgical robots will create a new medical ecology.

With Continuous Innovation and Improvement, RainMed Medical Has Built a Carrier grade Platform for Vascular Interventional Surgery Robots

In a complete vascular interventional surgery, doctors need to accurately operate guide wire, catheter, balloon, stent and other interventional instruments to achieve repeated puncture, push, withdrawal and other actions to achieve accurate diagnosis and treatment. To successfully enable vascular interventional surgery robot to imitate the operations of the medical instruments so as to accurately reach the location of the lesion and complete the diagnosis and treatment work efficiently, it requires profound accumulation of hardware and software technology. In order to enable the interventional robot to independently realize the precise surgical operations, RainMed Medical has determined a "three-step" strategic plan, researching and developing robotic technology step by step in order to develop an automated vascular interventional robot covering the whole process of diagnosis and treatment.

In this forum, Kangjian Liu introduced the latest progress and exploration of RainMed Medical. The company's FlashBot vascular interventional surgery robot has successfully conducted several animal experiments, and continues to optimize and upgrade. Different from ordinary interventional surgery robots that can only perform basic PCI operations, the FlashBot of RainMed Medical can realize automatic angiography guidance and push, rapid functional diagnosis, interventional channel construction, surgical navigation guidance, postoperative evaluation and management, and comprehensively cover all aspects of vascular interventional diagnosis and treatment. In the future, RainMed Medical will also sign the clinical experiment agreement of vascular interventional surgery robot with domestic well-known Class A hospitals. The close interaction with future users will accelerate the realization of the great vision of unmanned operating room.

At present, the world is generally faced with the problems of long training of new doctors, large gap in hospital resources, and unequal distribution of doctors and patients. Surgical robots can achieve medical balance in a short time, so that doctors can reach a stable level after a short period of learning. The clinical application of the automatic full-process vascular interventional surgery robot of RainMed Medical can reduce the amount of radiation of doctors, improve the standardization and precision of surgical operations, shorten the learning curve of doctors, reduce the regional medical level gap, so as to promote the level of cardiovascular interventional diagnosis and treatment in China to a new level.

The field of vascular interventional surgery robot is flourishing. Although the pattern of this emerging field has not been determined yet, its advanced diagnosis and treatment concept and excellent clinical value have attracted the attention of many investors and clinicians. At the same time, the issue of whether merger and integration will occur in the vascular interventional surgery robot industry has also aroused widespread discussion. To respond to this question, Mr. Kangjian Liu said that the merger and integration of vascular interventional surgery robot industry is necessary and inevitable.

In the future, RainMed is likely to carry out M&A and integration in the field of vascular interventional surgery robot, aiming at enterprises with special disease diagnosis and treatment technology. Surgery robot is a highly professional high-end medical equipment. Different subdivisions of the field have their own technical barriers. A mature vascular interventional surgery robot needs to comprehensively integrate a variety of diagnosis and treatment methods and interventional consumables. Therefore, in this process, it is necessary to merge and acquire technologies in the segmented fields to make the interventional surgery robot adapt to the requirements of different vessels and surgical methods.

Therefore, RainMed medical will strive to make the vascular interventional surgery robot become a carrier grade so that it can perform PCI of the traditional interventional surgery robot as well as a variety of specialized diagnosis and treatment. This will help to build an integrated diagnosis and treatment program for vascular diseases in the operating room, and promote the high-quality development of vascular diseases in the country.

"At the moment, high-level doctors represent the hospital level and the top of the surgical level. One day, surgical robots will help doctors perform higher-level surgeries on a large scale, and people will get used to choosing surgical robots as a necessary and inevitable choice for more precise, reliable, and less invasive surgery. This is the future we all look forward to."

Mr. Kangjian Liu said that although there are still many challenges in the research and development and promotion of surgical robots, RainMed Medical will always stay true to its original aspiration and devote itself to scientific research. In line with the purpose of "Targeted medical services for people's health", the company will build platform-level vascular interventional surgery robots to promote the realization of an unmanned operating room with automated diagnosis and treatment.